Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice

被引:332
作者
Ishii, S [1 ]
Shimizu, T [1 ]
机构
[1] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan
基金
日本科学技术振兴机构;
关键词
D O I
10.1016/S0163-7827(99)00016-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid: mediator. Although PAF was initially recognized for its potential to induce platelet aggregation and secretion, intense investigations have elucidated potent biological actions of PAF in a broad range of cell types and tissues, many of which also produce the molecule. PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor. PAF receptor is linked to intracellular signal transduction pathways, including turnover of phosphatidylinositol, elevation in intracellular calcium concentration, and activation of kinases, resulting in versatile bioactions, On the basis of numerous pharmacological reports, PAF is thought to have many pathophysiological and physiological functions. Recently advanced molecular technics enable us not only to clone PAF receptor cDNAs and genes, but also generate PAF receptor mutant animals, i.e., PAF receptor-overexpressing mouse and PAF receptor-deficient mouse. These mutant mice gave us a novel ana specific approach for identifying the pathophysiological and physiological functions of PAF. This review also describes the phenotypes of these mutant mice and discusses them by referring to previously reported pharmacological and genetical data. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:41 / 82
页数:42
相关论文
共 372 条
[1]  
ABBOTT CM, 1994, MAMM GENOME, V5, pS51
[2]   PAF analogues capable of inhibiting PAF acetylhydrolase activity suppress migration of isolated rat cerebellar granule cells [J].
Adachi, T ;
Aoki, J ;
Manya, H ;
Asou, H ;
Arai, H ;
Inoue, K .
NEUROSCIENCE LETTERS, 1997, 235 (03) :133-136
[3]   Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle:: PAF stimulates NO, VEGF, and FAKpp125 [J].
Ahmed, A ;
Dearn, S ;
Shams, M ;
Li, XF ;
Sangha, RK ;
Rola-Pleszczynski, M ;
Jiang, JQ .
FASEB JOURNAL, 1998, 12 (10) :831-843
[4]   PLATELET-ACTIVATING-FACTOR STIMULATES PHOSPHOLIPASE-C ACTIVITY IN HUMAN ENDOMETRIUM [J].
AHMED, A ;
SMITH, SK .
JOURNAL OF CELLULAR PHYSIOLOGY, 1992, 152 (01) :207-214
[5]  
Akagi M, 1997, ARZNEIMITTEL-FORSCH, V47, P1364
[6]   Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist [J].
Albert, DH ;
Magoc, TJ ;
Tapang, P ;
Luo, GJ ;
Morgan, DW ;
Curtin, M ;
Sheppard, GS ;
Xu, LH ;
Heyman, HR ;
Davidsen, SK ;
Summers, JB ;
Carter, GW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 325 (01) :69-80
[7]   ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats [J].
Albert, DH ;
Luo, GJ ;
Magoc, TJ ;
Tapang, P ;
Holms, JH ;
Davidsen, SK ;
Summers, JB ;
Carter, GW .
SHOCK, 1996, 6 (02) :112-117
[8]  
ALECOZAY AA, 1991, J REPROD FERTIL, V91, P301
[9]   Role of phospholipase C beta 3 phosphorylation in the desensitization of cellular responses to platelet-activating factor [J].
Ali, H ;
Fisher, I ;
Haribabu, B ;
Richardson, RM ;
Snyderman, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) :11706-11709
[10]  
ALI H, 1994, J BIOL CHEM, V269, P24557